US5945422A
(en)
*
|
1997-02-05 |
1999-08-31 |
Warner-Lambert Company |
N-oxides of amino containing pyrido 2,3-D! pyrimidines
|
US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
CZ20022475A3
(cs)
*
|
2000-01-25 |
2003-03-12 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidin-2,7-diaminové inhibitory kinázy
|
US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
US6518276B2
(en)
*
|
2000-08-31 |
2003-02-11 |
Syntex (U.S.A.) Llc |
7-oxo-pyridopyrimidines (II)
|
EP1506962B1
(en)
*
|
2000-10-20 |
2008-07-02 |
Eisai R&D Management Co., Ltd. |
Nitrogen-containing aromatic heterocycles
|
CN100525768C
(zh)
*
|
2000-10-23 |
2009-08-12 |
史密丝克莱恩比彻姆公司 |
新化合物
|
WO2002064594A2
(en)
|
2001-02-12 |
2002-08-22 |
F. Hoffmann-La Roche Ag |
6-substituted pyrido-pyrimidines
|
US20030105115A1
(en)
*
|
2001-06-21 |
2003-06-05 |
Metcalf Chester A. |
Novel pyridopyrimidines and uses thereof
|
AU2003211594A1
(en)
*
|
2002-03-05 |
2003-09-16 |
Eisai Co., Ltd. |
Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
|
EP1499320B1
(en)
*
|
2002-04-19 |
2007-08-22 |
Smithkline Beecham Corporation |
Novel compounds
|
WO2004013633A2
(en)
*
|
2002-07-29 |
2004-02-12 |
Axxima Pharmaceuticals Ag |
Method for isolating atp binding proteins by means of immobolized protein inhibitors
|
ES2293064T3
(es)
*
|
2002-08-06 |
2008-03-16 |
F. Hoffmann-La Roche Ag |
6-alcoxi-pirido-pirimidinas como inhibidores de la p-38 map quinasa.
|
WO2004024895A2
(en)
*
|
2002-09-16 |
2004-03-25 |
Plexxikon, Inc. |
Crystal structure of pim-1 kinase
|
WO2004043367A2
(en)
*
|
2002-11-06 |
2004-05-27 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds and use thereof
|
JP2006508997A
(ja)
*
|
2002-11-28 |
2006-03-16 |
シエーリング アクチエンゲゼルシャフト |
Chk−、Pdk−およびAkt−阻害性ピリミジン、それらの製造および薬剤としての使用
|
WO2004063195A1
(en)
*
|
2003-01-03 |
2004-07-29 |
Sloan-Kettering Institute For Cancer Research |
Pyridopyrimidine kinase inhibitors
|
WO2004080462A1
(ja)
*
|
2003-03-10 |
2004-09-23 |
Eisai Co., Ltd. |
c-Kitキナーゼ阻害剤
|
WO2004087651A2
(en)
*
|
2003-03-27 |
2004-10-14 |
Merck & Co. Inc. |
Formulations for tyrosine kinase inhibitors
|
TW200502236A
(en)
*
|
2003-03-28 |
2005-01-16 |
Hoffmann La Roche |
Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
|
WO2005044788A1
(ja)
*
|
2003-11-11 |
2005-05-19 |
Eisai Co., Ltd. |
ウレア誘導体およびその製造方法
|
CA2544247A1
(en)
*
|
2003-11-13 |
2005-05-26 |
David Michael Goldstein |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
ATE481134T1
(de)
|
2004-01-21 |
2010-10-15 |
Univ Emory |
Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
|
SG150544A1
(en)
*
|
2004-03-15 |
2009-03-30 |
Hoffmann La Roche |
Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivatives, their manufacture and use as pharmaceutical agents
|
FR2873118B1
(fr)
*
|
2004-07-15 |
2007-11-23 |
Sanofi Synthelabo |
Derives de pyrido-pyrimidine, leur application en therapeutique
|
KR20070053205A
(ko)
|
2004-09-17 |
2007-05-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
의약 조성물
|
CN101014600A
(zh)
*
|
2004-09-21 |
2007-08-08 |
霍夫曼-拉罗奇有限公司 |
用作蛋白激酶抑制剂的6-(2-烷基-苯基)-吡啶并[2,3-d]嘧啶类
|
US20070054916A1
(en)
*
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
US8093273B2
(en)
*
|
2004-10-20 |
2012-01-10 |
Resverlogix Corp. |
Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
|
TW200724142A
(en)
*
|
2005-03-25 |
2007-07-01 |
Glaxo Group Ltd |
Novel compounds
|
PE20100737A1
(es)
|
2005-03-25 |
2010-11-27 |
Glaxo Group Ltd |
Nuevos compuestos
|
US20090137550A1
(en)
*
|
2005-03-25 |
2009-05-28 |
Glaxo Group Limited |
Novel Compounds
|
KR20080002865A
(ko)
*
|
2005-03-25 |
2008-01-04 |
글락소 그룹 리미티드 |
피리도[2,3-d]피리미딘-7-온 및3,4-디히드로피리미도[4,5-d]피리미딘-2(1h)-온유도체의 제조 방법
|
FR2887882B1
(fr)
*
|
2005-07-01 |
2007-09-07 |
Sanofi Aventis Sa |
Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
|
KR101431279B1
(ko)
|
2005-07-29 |
2014-08-20 |
리스버로직스 코퍼레이션 |
복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달
|
EP1925941B1
(en)
*
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
AU2006285673B2
(en)
*
|
2005-09-01 |
2010-12-02 |
Eisai R&D Management Co., Ltd. |
Method for preparation of pharmaceutical composition having improved disintegratability
|
EP1949902B1
(en)
*
|
2005-11-07 |
2012-06-27 |
Eisai R&D Management Co., Ltd. |
USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
|
WO2007061130A1
(ja)
*
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
多発性骨髄腫に対する抗腫瘍剤
|
FR2896246B1
(fr)
*
|
2006-01-13 |
2008-08-15 |
Sanofi Aventis Sa |
Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
|
EP2036557B1
(en)
*
|
2006-05-18 |
2015-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
JPWO2008001956A1
(ja)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝線維症治療剤
|
CN101511793B
(zh)
*
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
EP2094698A1
(en)
*
|
2006-11-09 |
2009-09-02 |
F. Hoffmann-Roche AG |
Substituted 6-phenyl-pyrido [2,3-d]pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
|
FR2910813B1
(fr)
*
|
2006-12-28 |
2009-02-06 |
Sanofi Aventis Sa |
Nouvelle utilisation therapeutique pour le traitement des leucemies
|
EP2119707B1
(en)
*
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
MX2009008099A
(es)
|
2007-02-01 |
2009-12-14 |
Resverlogix Corp |
Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
|
WO2008104473A2
(en)
*
|
2007-02-28 |
2008-09-04 |
F. Hoffmann-La Roche Ag |
Pyrazolopyriidine derivatives and their use as kinase inhibitors
|
US20100063032A1
(en)
*
|
2007-03-28 |
2010-03-11 |
Debenham John S |
Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
|
EP2218712B1
(en)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
KR101506062B1
(ko)
*
|
2008-01-29 |
2015-03-25 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 저해 물질과 탁산의 병용
|
JP5602728B2
(ja)
|
2008-06-26 |
2014-10-08 |
レスバーロジックス コーポレイション |
キナゾリノン誘導体の製造方法
|
EP2382194B1
(en)
|
2009-01-08 |
2014-03-12 |
Resverlogix Corp. |
Compounds for the prevention and treatment of cardiovascular disease
|
WO2010106436A2
(en)
|
2009-03-18 |
2010-09-23 |
Resverlogix Corp. |
Novel anti-inflammatory agents
|
SI2421533T1
(sl)
|
2009-04-22 |
2019-01-31 |
Resverlogix Corp. |
Nova protivnetna sredstva
|
WO2011159726A2
(en)
|
2010-06-14 |
2011-12-22 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
AU2011270165B2
(en)
|
2010-06-25 |
2015-12-24 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
US8623889B2
(en)
*
|
2010-12-17 |
2014-01-07 |
Genentech, Inc. |
Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
DK2773354T3
(da)
|
2011-11-01 |
2019-08-05 |
Resverlogix Corp |
Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
WO2014080291A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Biaryl derivatives as bromodomain inhibitors
|
WO2014080290A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Cyclic amines as bromodomain inhibitors
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
CA2895905A1
(en)
|
2012-12-21 |
2014-06-26 |
Zenith Epigenetics Corp. |
Novel heterocyclic compounds as bromodomain inhibitors
|
MX368099B
(es)
|
2013-05-14 |
2019-09-19 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
|
BR112016022056B1
(pt)
|
2014-03-26 |
2023-04-11 |
Astex Therapeutics Limited |
Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
SI3263106T1
(sl)
|
2015-02-25 |
2024-02-29 |
Eisai R&D Management Co., Ltd. |
Postopek zatiranja grenkobe derivata kinolina
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
EP3268007B1
(en)
|
2015-03-13 |
2022-11-09 |
Resverlogix Corp. |
Compositions and therapeutic methods for the treatment of complement-associated diseases
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
WO2018069232A1
(en)
|
2016-10-10 |
2018-04-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of having cardiac hypertrophy
|